This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05144386
Recruitment Status : Recruiting
First Posted : December 3, 2021
Last Update Posted : November 7, 2023
Sponsor:
Information provided by (Responsible Party):
Excision BioTherapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a First in Human (FIH) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable antiretroviral therapy (ART).

Condition or disease Intervention/treatment Phase
HIV-1-infection Biological: EBT-101 Phase 1

Detailed Description:

This is a FIH, open-label, sequential cohort, single ascending dose (SAD) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable ART.

Participants will be asked to attend several visits for screening to determine eligibility. On Day 1, eligible participants will receive a single IV dose of EBT-101. All participants will be assessed for eligibility for an analytical treatment interruption (ATI) of their background ART at Week 12. All participants will be followed through Week 48 (end of study). Participants are required to attend multiple study visits at the clinical site including daily visits for the first 14 days, followed by weekly visits after Week 12 for ATI participants. Non-ATI participants are followed monthly after Week 12.

Eligible participants who are enrolled in the FIH study (EBT-101-001) will also be enrolled in a separate Long Term Follow Up (LTFU) study (EBT-101-002) for safety monitoring. The duration of the LTFU study is 15 years.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2a, Sequential Cohort, Single Ascending Dose Study of the Safety, Tolerability, Biodistribution, and Pharmacodynamics of EBT 101 in Aviremic HIV-1 Infected Adults on Stable Antiretroviral Therapy
Actual Study Start Date : January 24, 2022
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : March 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: EBT-101 Dose-Level 1
Cohort A: Participants will be administered dose-level 1 of EBT-101
 Biological: EBT-101
EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration
Experimental: EBT-101 Dose-Level 2
Cohort B: Participants will be administered dose-level 2 of EBT-101
 Biological: EBT-101
EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration
Experimental: EBT-101 Dose-Level 3
Cohort C: Participants will be administered dose-level 3 of EBT-101
 Biological: EBT-101
EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and Tolerability of EBT-101 [ Time Frame: 48 weeks ]
    Safety and tolerability of EBT-101 will be assessed based on the incidence and severity of adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 48 weeks


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Cohorts A and B will enroll male adults (sex at birth)
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (abbreviated):

  • Willing to enroll and sign the written informed consent for EBT-101-001 (current study) and EBT-101-002, the LTFU study.
  • Age between 18 and 70 years (both inclusive).
  • Body weight ≥55 and ≤110 kg.
  • Cohorts A and B will only enroll male subjects (sex at birth).
  • Chronic HIV-1 with known subtype B infection
  • On stable regimen defined as continuous ART suppressive treatment with HIV RNA level below the level of quantitation for >1 years prior to screening
  • Plasma HIV-1 RNA levels below the limit of quantitation during screening.
  • Peripheral blood CD4 T cell count ≥500 cells/mm3 for at least 2 years prior to screening
  • Willing and able to comply, as assessed by the Investigator, with all study-related procedures.
  • Have previously been vaccinated for N. meningitidis with documented history and/or received a N. meningitidis vaccination prior to dosing.
  • Willing to stop ART if eligible for analytical treatment interruption.
  • Willing to comply with the measures to prevent HIV transmission and reinfection required by the protocol.
  • Must have received a COVID-19 vaccination series and boosters as specified by current federal (CDC) recommendations, with the last dose ≥30 days prior to dosing.

Exclusion Criteria (abbreviated):

  • Documented prior HIV-1 drug resistance to ≥2 or more classes of ART defined as single key mutations or an accumulation of minor mutations that result in resistance to entire respective drug classes within the past 5 years.
  • History of >1 change in ART due to virologic failure during preceding 2 years prior to screening.
  • Received in the preceding 12 months or HCP plans to prescribe long-acting injectable ART.
  • Pregnant or breastfeeding or planning to become pregnant (self or partner) or to breastfeed at any time through 48 weeks post dose.
  • History of HIV dementia.
  • History of progressive multifocal leukoencephalopathy.
  • History of significant cardiac disease in last 2 years.
  • History of HIV-related kidney disease with abnormal renal function.
  • History of pre-HIV treatment nadir CD4 T cell count <200 cells/mm3 or post-HIV treatment confirmed CD4+ <200 cells/mm3.
  • History of AIDS-defining opportunistic infection prior to screening.
  • Evidence of acute or chronic hepatitis B and/or hepatitis C.
  • Known history or diagnosis of liver cirrhosis.
  • Diagnosis of nonalcoholic fatty liver or advanced nonalcoholic steatohepatitis.
  • Abnormal laboratory values in hematology, hepatic, renal, peripheral blood CD4 T cell count <500 cells/mm3, and other systems for lab safety screening.
  • Known history of positive tuberculin skin test.
  • Receipt of any investigational HIV vaccine (prophylactic and/or therapeutic) within the year prior to screening.
  • Receipt of any gene therapy product approved or experimental, at any time.
  • Anti-AAV9 serum neutralizing antibodies (Nabs) >1:20 titer.
  • Known positive SARS-CoV-2 test within 48 hours prior to planned dosing date.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05144386


Contacts
Layout table for location contacts
Contact: William Kennedy, MD 833-214-2241 clinicalscience@excisionbio.com
Contact: Study Lead at ExcisionBio clinicalscience@excisionbio.com

Locations
Layout table for location information
United States, California
University of California San Francisco Withdrawn
San Francisco, California, United States, 94110
Quest Clinical Research Recruiting
San Francisco, California, United States, 94115
Contact: Jason Lane    415-353-0800 ext 37    jason@questclinical.com   
Contact: Tory Harwin    415-353-0800    tory@questclinical.com   
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Michael Klebert    314-454-0058    mklebert@wustl.edu   
United States, New Jersey
Cooper Health Active, not recruiting
Camden, New Jersey, United States, 08103
Sponsors and Collaborators
Excision BioTherapeutics
Investigators
Layout table for investigator information
Study Director: William Kennedy, MD Excision BioTherapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Excision BioTherapeutics
ClinicalTrials.gov Identifier: NCT05144386    
Other Study ID Numbers: EBT-101-001
First Posted: December 3, 2021    Key Record Dates
Last Update Posted: November 7, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Excision BioTherapeutics:
CRISPR
Gene Therapy
AAV9
HIV